Defect in the membrane expression of high affinity 72-kD Fc gamma receptors on phagocytic cells in four healthy subjects.

J L Ceuppens, … , F Van Vaeck, C L Anderson


Three different receptors for the Fc portion of IgG (FcR) have been characterized on human leukocytes. We have identified four healthy members of one family, whose blood phagocytic cells lack functional 72 kD high-affinity FcRI. Their monocytes were unable to bind the Fc portion of mouse (m)-IgG2a and of monomeric human IgG, and they were unreactive with two anti-FcRI monoclonal antibodies. Thus, FcRI is either absent, expressed at very low density, or is so structurally altered as to be unable to bind both its ligand and the anti-FcRI antibodies. The failure to bind the Fc portion of mIgG2a underlies the previously reported inability of these monocytes to support T cell mitogenesis on OKT3 stimulation. FcRI was not inducible upon incubation of their monocytes or neutrophils in gamma interferon. However, their monocytes were able to bind aggregated human IgG, and to phagocytose IgG-coated particles in vitro. Both functions could be blocked with a monoclonal antibody to the 40-kD low-affinity FcRII and therefore apparently were mediated exclusively through FcRII. This also demonstrates that FcRII can mediate phagocytosis independently. Despite the FcRI defect, these subjects had no circulating immune complexes, no evidence of autoimmune pathology and no increased susceptibility to infections.

Find the latest version:

https://jci.me/113634/pdf
Defect in the Membrane Expression of High Affinity 72-kD Fc γ Receptors on Phagocytic Cells in Four Healthy Subjects

Jan L. Ceuppens,* Miren L. Baroja,* Frieda Van Vaek,* and Clark L. Anderson†
*Division of Clinical Immunology, Department of Medicine, University of Leuven, 3000 Leuven, Belgium; and the †Department of Medicine, The Ohio State University, Columbus, Ohio 43210

Abstract

Three different receptors for the Fc portion of IgG (FcR) have been characterized on human leukocytes. We have identified four healthy members of one family, whose blood phagocytic cells lack functional 72 kD high-affinity FcRI. Their monocytes were unable to bind the Fc portion of mouse (m)-IgG2a and of monomeric human IgG, and they were unreactive with two anti-FcRI monoclonal antibodies. Thus, FcRI is either absent, expressed at very low density, or is so structurally altered as to be unable to bind both its ligand and the anti-FcRI antibodies. The failure to bind the Fc portion of mIgG2a underlies the previously reported inability of these monocytes to support T-cell mitogenesis on OKT3 stimulation. FcRI was not inducible upon incubation of their monocytes or neutrophils in gamma interferon. However, their monocytes were able to bind aggregated human IgG, and to phagocytose IgG-coated particles in vitro. Both functions could be blocked with a monoclonal antibody to the 40-kD low-affinity FcRII and therefore apparently were mediated exclusively through FcRII. This also demonstrates that FcRII can mediate phagocytosis independently. Despite the FcRI defect, these subjects had no circulating immune complexes, no evidence of autoimmune pathology and no increased susceptibility to infections.

Introduction

Three distinct types of Fc receptors for IgG (FcR)¹ have been identified on human leukocytes (for review see 1). A high affinity receptor (FcRI) of 72 kD is present on monocytes and macrophages (2–6). Neutrophils express this receptor after overnight incubation in gamma-interferon (7). A low affinity FcR (FcRII) of 40 kD (the CDw32 antigen) has a broader range of cellular expression, being present not only on mono-

nuclear phagocytes but also on granulocytes, platelets, and B-lymphocytes (4, 8, 9). A third type of FcR (FcRIII) (the CD16 antigen) has a molecular weight from 50 to 70 kD, is expressed by macrophages (but not monocytes), neutrophils, eosinophils (sparse), and subsets of lymphocytes (T-gamma cells and natural killer cells) (10–13). The 72-kD FcR binds monomeric human (Hu) IgG1 and IgG3 with a Kₜ of 10⁸–10⁹ M⁻¹, and 1–4 × 10⁴ receptors are present per monocyte (5, 6). In contrast HuIgG binds to FcRII only when it is present as a complex (either soluble complexes or IgG-coated particles) (4, 14). The specificity of the monocytic receptors for murine (m) subclasses is quite distinctive. FcRI binds mIgG2a and mIgG3 with high affinity (4, 15), while FcRII binds mIgG1 and mIgG2b, although to be detected, binding must be enhanced by using low ionic strength conditions or ligand complexes (4, 14, 15).

FcRs are important for the clearance of immune-complexes and for internalization of IgG-coated cells or organisms. Defective FcR function has been associated with certain HLA-haplotypes and with immune complex disease susceptibility (16–18). FcR triggering can stimulate cell metabolism, e.g., chemiluminescence of phagocytic cells (3). Moreover, FcRs might be important for antigen presentation (19, 20), and FcRs on phagocytic cells and NK cells are essential for extracellular killing in antibody-dependent cellular cytotoxicity (21, 22). No functional differentiation between the distinct types of FcRs expressed on the same cell-type has been found yet and the relative importance of the three FcRs in mediating immunophagocytosis is not known.

We describe four healthy subjects, belonging to one kindred, apparently lacking functional FcRI. We have previously reported on these subjects as “OKT3 nonresponders,” indicating the lack of proliferative T cell responses to the monoclonal anti-CD3 antibody OKT3 (and to other anti-CD3 antibodies of the mIgG2a subclass) in cultures of peripheral blood mononuclear cells (PBMC) (23, 24). Unresponsiveness was observed in four among the seven children of one family and was not related to a particular HLA-haploype (23). The identification of these subjects was a fortuitous one, made while we were determining normal values for proliferative responses of PBMC to OKT3 on a large series of healthy donors. T cell stimulation in this system requires interactions of anti-CD3 with CD3 on the T cell membrane and with monocyte FcRs (24, 25). We reported that monocytes from non-responders were unable to bind the Fc part of mIgG2a (24) and that this inability to bind mIgG2a underlies the inability of the monocytes to support mIgG2a anti-CD3-induced T-cell mitogenesis. We have now further explored this lack of mIgG2a binding to monocytes, and report here that it is based on a new and interesting defect of FcRI expression. The absence, low density expression, or afucnctionality of this receptor is not associated with any disease. The significance of the FcRI defect remains to be determined.

Address reprint requests to Dr. J. L. Ceuppens, Laboratory of Clinical Immunology, University Hospitals, Capucienenvoer 33, B-3000 Leuven, Belgium. Dr. Baroja is on leave from the Centro Nacional de Enfermedades Reumaticas, Caracas, Venezuela.

Part of this work has been presented as a poster at the National Meeting of the American Rheumatism Association, Washington, DC, June 1987 and as an oral presentation at the First International Waaler Conference, December 1987, Bergen, Norway.

Received for publication 29 September 1988 and in revised form 10 February 1988.

1. Abbreviations used in this paper: FcR, Fc receptor for IgG; HuIgG, human IgG; Hu-RBC, human red blood cells; mIgG, murine IgG.

© The American Society for Clinical Investigation, Inc.
0021-9738/88/08/0571/08 $2.00
Volume 82, August 1988, 571–578

571
Defective Fc Receptor Expression
Methods

Subjects. The four subjects, previously indetified as "OKT3 nonresponders" (23, 24), are four sisters, aged 32, 27, 26, and 19 years. They are clinically healthy and have no history of repeated or protracted infections, and no clinical features indicating autoimmune or immune complex pathology. There is no evidence for consanguinity of the parents. Control subjects (OKT3-responders) were healthy, aged 20–50. Blood was drawn after informed consent.

Monoclonal antibodies. The murine monoclonal anti-CD3 antibody OKT3 (unlabeled and FITC-conjugated), was purchased from Ortho Diagnostics (Beerse, Belgium). The antibody was centrifuged at 100,000 g or 30 min before use in immunofluoresence experiments. Monoclonal antibodies to FcRs were previously described (3, 4, 12). Ab 32.2 is a mlgG1 antibody against FcRI. A second mlgG1 antibody against FcRI (Ab 44.1) detecting a different epitope, was a gift from Dr. P. Gyuere (Dartmouth Medical School, Hanover, NH). Ab IV.3 is a mlgG2b antibody against FcRII. Hybridoma supernatants were used for all the experiments. It has previously been excluded that these antibodies bind to FcRs through their Fe part (4). Anti-Leu 11b (an IgM antibody against FcRIII) and OKM1 (an mlgG2b antibody against the C3bi receptor [CD11b]), were purchased from Becton Dickinson (Erembodegem, Belgium) and Ortho Diagnostics (Beerse, Belgium).

Other reagents. Human Cohn fraction II (Sigma Chemical Co., St. Louis, MO) was used as a source of HulgG. FITC-conjugated HulgG was purchased from Cappel Laboratories (Malvern, PA). A 1-ng/ml solution of both preparations was made up in PBS pH 7.2. To prepare monomeric IgG, the solution was centrifuged at 100,000 g for 30 min and only the top two-thirds of the supernatant was used. To prepare aggregated IgG the solution was heated at 64°C for 30 min and centrifuged at 20,000 g for 30 min to remove insoluble aggregates. Recombiant human gamma-interferon was purchased from Janssen Chimica (Beerse, Belgium).

Cell separation. PBMC were isolated from heparinized blood on Ficoll-Hypaque (density 1.077) gradients. T cells and non-T cells were separated by rosetting with 2-aminooethylisothiouronium bromide (AET)-treated sheep red blood cells (SRBC) as reported (27). Nonrosetting cells containing less than 3% OKT3-reactive cells, were > 50% peroxidase-positive, and were used as a source of monocytes. Neutrophils were isolated from the pellet of the Ficoll-Hypaque gradients. Red blood cells (RBC) were lysed with ammonium chloride.

Cell cultures. For antigenic stimulation, PBMC were resuspended in culture medium of RPMI 1640 (Gibco, Gent, Belgium) containing 2 mM L-glutamine, penicillin (100 U/ml), streptomycin (100 μg/ml) and supplemented with 5% normal human serum (NHS). Cell concentration was 10^6/ml, and 200 μl cell suspension was cultured in round-bottom microculture plates. Antibodies were added against predetermined optimal concentrations: tetanus toxoid (Wyeth, Marietta, PA) 1 Lfu/ml; streptokinase-streptodornase (Lederle Laboratories, Wayne, NJ) 50 U/ml; Candida-antigen (Haarlem Allergen Laboratories, The Netherlands) 50 μg/ml; influenza antigen (Duphar, Brussels, Belgium) 1/2,000 final dilution. All cultures were performed in quadruplicate at 37°C in a humidified 5% CO2 atmosphere. After 6 d of culture, cells were pulsed with 1 μCi of [3H]thymidine (specific activity 2 Ci/mmol, Amersham Ltd., Amersham, UK) and 8 h later, cells were harvested with a MASH II and radioactivity on the filter papers was counted. To study the effect of gamma interferon on FcR expression, monocytes and neutrophils were cultured at a concentration of 10^6 cells/ml in Teflon jars, in culture medium containing 12% NHS and 5 x 10^-4 M mercaptoethanol, with or without recombinant gamma interferon (100 U/ml).

Immunofluorescence. To study the binding of IgG to monocyte FcRs, non-T cells (0.5 x 10^6) in a 50-μl vol of PBS with 1% BSA (pH 7.4) were incubated with the ligand for 30 min at 4°C. This was either monomeric OKT3-FITC (0.5 μg), monomeric HulgG-FITC (2 and 0.5 μg) or aggregated HulgG-FITC (8, 2, and 0.5 μg) in a 50-μl volume. This corresponds to final concentrations of the ligand of 80, 20, and 5 μg/ml. After incubation, cells were washed twice in PBS-BSA, and fixed in 1% paraformaldehyde. In some experiments, in order to block the binding of FITC-conjugated IgG to FcRs, cells were preincubated with a fivefold excess of unlabeled HulgG or of mlgG2a or with 10 μl of monoclonal anti-FcRII Ab IV.3 (at 4°C for 30 min), before the FITC-conjugated ligand (OKT3-FITC or HulgG-FITC) was added.

To detect autologous cytokilic IgG on monocytes, freshly isolated non-T cells in 50 μl of PBS-BSA were incubated at 4°C for 30 min with 50 μl of FITC-conjugated F(ab')2 fragments of goat anti-HulgG (1/40) (Tago, Burlingame, CA). After washing, cells were fixed in paraformaldehyde as described above.

For staining with monoclonal antireceptor antibodies, non-T cells or neutrophils in a 50 μl volume of PBS-BSA were incubated with 10 μl of monoclonal antibody 32.2, 44.1, IV.3 (diluted 1/10), OKM1 (20 μg/ml), anti-Leu 11b (50 μg/ml), or a control monoclonal antibody of the mlgG1 subclass (anti-Leu 4) (20 μg/ml) (as a control for nonspecific binding). Cells were washed twice, and then further incubated with FITC-conjugated F(ab')2 fragments of goat anti-mlgG or of anti-mlgM (for staining with anti-Leu 11b) (Tago) (50 μl of a 1/40 dilution in PBS-BSA) for 30 min at 4°C. After two washings, cells were fixed in 1% paraformaldehyde.

Before analysis, cells were washed and resuspended in one ml of PBS. They were then analyzed on a FACS-Star (Becton-Dickinson). The setting was set around the monocyte or neutrophil population and 5,000 cells were analyzed for fluorescence.

Binding of radiolabeled HulgG. Monomeric HulgG (Cohn fraction II, 12 mg/ml, centrifuged for 30 min at 100,000 g) was labeled with 125I by the chloramine T method to a specific activity of 4 μCi/μg. The solution was centrifuged at 20,000 g to remove insoluble aggregates, the concentration was adjusted to 20 μg/ml in PBS-BSA, and a twofold serial dilution was made. E-rosette negative cells (at a concentration of 10 to 15 x 10^6 peroxidase-positive cells per ml) in medium with 50% FCS were preincubated in plastic tubes at 4°C with Ab IV.3 (in order to block FcRII). We then added 125I-IgG in final concentrations of 6 to 0.37 μg/ml to the cell suspensions, and further incubated the mixture for 45 min at 4°C. Final cell concentration was 3-4.5 x 10^5 monocytes/ml. To determine nonspecific binding of 125I-IgG, part of the cells were incubated with cold IgG (6 mg/ml) before the radiolabeled ligand was added. Nonspecific binding represented < 0.01% of the total radioactivity. After extensive washing, radioactivity bound to the cells was determined.

Rosetting with anti-D coated human RBC. Human D-positive RBC were sensitized with human anti-D antisemum (Ortho Diagnostics) and resuspended as a 1% solution in HBSS. 200 μl of the suspension was mixed with 100 μl of E-rosette-negative cells (1 x 10^7 cells/ml), centrifuged at 100 g for 5 min, and incubated at 4°C for 60 min. In some experiments the E-rosette negative cells were preincubated with 20 μl of Ab IV.3 to block FcRII. After gentle resuspension, the number of rosette-forming monocytes was counted microscopically in a hemocytometer.

Monocyte phagocytosis assay. FcR-mediated phagocytosis by monocytes was evaluated by an assay similar to the one reported by Salmon et al. (17). SRBC (10^6 cells/ml) were sensitized with a maximal subaglutinating dose of rabbit anti-SRBC antisemum (Behringwerke, Marburg, FRG). In some experiments, a twofold serial dilution of the antisemum was used to prepare SRBC that were suboptimally opsonized. To the mixture of SRBC and antisemum, 50 μCi of 51Cr was added. After a 1-h incubation at 37°C, SRBC were washed in PBS and resuspended in culture medium with 10% FCS at a concentration of 10^7/ml. The FCS used was heat-inactivated and absorbed with SRBC. 100-μl samples of PBMC or E-rosette negative cells (adjusted to a concentration of 5 x 10^6 peroxidase-positive cells per ml in medium with 10% FCS) were combined with 200 μl containing varying numbers of 51Cr labeled SRBC, either nonsensitized or sensitized with anti-SRBC antibodies. This resulted in monocyte/erythrocyte ratios of 1/10, 1/20, and 1/40. The mixture was centrifuged for 3 min at 1000 rpm and incubated at 37°C for 1 h. SRBC were then lysed with ammonium chloride in Tris buffer. The remaining cells were washed four
times, and the resulting sediment was counted in a gamma counter (Packard Instruments, Inc., Downers Grove, IL) to determine mononuclear cell-associated $^{14}$Cr. Results are expressed as the mean number of SRBC phagocytosed per monocyte per hour, calculated after subtraction of the counts in the unsonopized SRBC control.

Other immunological tests. Antinuclear and antitissie antibodies in serum were measured with standard indirect immunofluorescent techniques on Hep-2 cells and on frozen tissue sections, respectively (28). Serum immune-complexes were detected by binding to solid-phase C1q and monoclonal rheumatoid factor (mRF) as previously reported (29). Serum immunoglobulins (A, G and M) were measured with a standard nephelometric immunoassay (Hyland Travenol Laboratories, Costa Mesa, CA). In vivo specific antibody production was studied by immunization with hepatitis B-surface antigen. Three injections of the commercial Pasteur vaccine (Hevac B) were given intramuscularly with a 1-min interval, and a fourth (booster) injection was given 1 yr later. Antibody levels were determined with the commercially available RIA (Abbott Laboratories, North Chicago, IL).

Results

Nonresponder monocytes do not bind monomeric mIgG2a or HulG. We have reported (24) that monocytes from “OKT3-nonresponders” are unable to bind the Fc part of mlgG2a in an indirect immunofluorescence assay. We reexamined the FcR binding of mlgG2a to the monocytes with monomeric FITC-conjugated OKT3. Responder monocytes but not nonresponder monocytes were able to bind OKT3-FITC (not shown). Preincubation with unlabeled mlgG2a completely inhibited the binding of OKT3-FITC to the responder monocytes. In view of the reported specificity of the two distinct monocyte FcRs for mlgG subclasses (FcRI binds mlgG2a and FcRII binds mlgG1 and mlgG2b) the results suggested that the defect in nonresponder-monocytes is at the level of FcRI. We also studied the interaction of monocytes with HulG. We first incubated the cells with FITC-conjugated HulG. Monomeric HulG-FITC bound to responder monocytes, but not to nonresponder monocytes (Fig. 1). Monomeric HulG has been shown to bind to FcRII only (1–6), and the lack of binding to nonresponder monocytes thus further argues for a defect of FcRI expression. Both responder and nonresponder monocytes were able to bind aggregated HulG-FITC (Fig. 1). However, when the cells were incubated with decreasing doses of this ligand, the capacity of nonresponder monocytes to bind aggregated HulG-FITC was found to be lower than for responder monocytes (Fig. 1). Binding of aggregated HulG-FITC was blocked by unlabeled aggregated HulG (not shown). Binding of aggregated HulG-FITC to nonresponder monocytes was also blocked with the anti-FcRII monomolecular antibody IV.3 (which has been shown to block the ligand interaction of FcRII (4)) (Fig. 2). In contrast, Ab IV.3 only partially reduced the binding of aggregated HulG-FITC to responder monocytes. These results thus indicate that the binding of aggregated HulG to nonresponder monocytes is mediated exclusively through FcRII. Lack of binding of aggregated HulG to nonresponder monocytes in the presence of Ab IV.3 makes it unlikely that nonresponder subjects have a variant FcRI with low affinity for IgG. To detect low density expression of FcRI, a radiolabeled ligand binding assay was also used. Cells from two responders and two nonresponders were first incubated with Ab IV.3 to block FcRII and then incubated with $^{125}$I-HulG in concentrations ranging from 6 to 0.37 μg/ml. Nonspecific binding was determined by preincubation with excess cold IgG. At the highest concentration of

![Figure 1](attachment:image.png)
125I-HuIgG, 5100 and 8,100 IgG molecules were bound per responder monocyte. The counts per minute bound to the nonresponder monocytes were < 6% of the counts per minute bound to the responder monocytes. Low density expression of FcRI on nonresponder monocytes is therefore very unlikely.

The presence of autologous cytoplphilic IgG on freshly isolated monocytes was studied by immunofluorescence with FITC-conjugated F(ab')2 fragments of goat anti-HuIgG. While cytophilic IgG was present on freshly isolated monocytes from all responder subjects, nonresponder monocytes lacked any detectable cytophilic autologous IgG (Fig. 3). These results excluded the possibility that FcRI on nonresponder monocytes was blocked with immune complexes.

Nonresponder monocytes do not form rosettes with anti-D coated human red blood cells (Hu-RBC). Hu-RBC coated with human anti-D antibodies have been shown to form rosettes with U937 cells and monocytes through binding to FcRI (4, 30). Lack of binding to FcRI is apparently due to the low surface density of the D-antigen. The assay was carried out with E-rosette-negative cells from two responders and two nonresponders. A few monocytes (8 and 9%) from the two nonresponders formed poor rosettes (3 to 5 RBC/monocyte) with the Hu-RBC, and this was blocked by preincubation with Ab IV.3 to 3 and 2%, respectively. The majority of responder monocytes formed rosettes with more than 5 RBC/monocyte (69% in donor 1 and 60% in donor 2) and this was only partially reduced (to 50% rosettes in both donors) by preincubation with Ab IV.3.

Nonresponder monocytes do not react with anti-FcRI antibodies. We analyzed the expression of FcRI on monocytes with two monoclonal antibodies against epitopes on FcRI (Ab 32.2 and 44.1) in an indirect immunofluorescence assay. None of the nonresponder monocytes reacted with these two anti-FcRI antibodies either alone or combined, while all responder monocytes did (Fig. 4). These results indicate that nonresponder monocytes either do not express FcRI, or express FcRI below the level of detection of our assay, or that they express an altered FcRI, which does not express the epitopes recognized by Ab 32.2 and 44.1. The receptor for C3bi on leucocytes (detected with monoclonal antibody OKM1), was found to be present in normal density on the monocytes and neutrophils from nonresponders. Similarly, a normal density of FcRII was detected on neutrophils and NK-cells with the monoclonal antibody anti-Leu 11b (12). Monocytes from both responders and nonresponders lacked FcRIII. Both neutrophils and monocytes normally expressed the FcRII as detected with Ab IV.3 (not shown).

Gamma interferon does not induce FcRI expression on nonresponder monocytes or neutrophils. Gamma interferon has been shown to enhance the expression of FcRI on human monocytes (7, 31). We therefore cultured E-rosette-negative cells (10^6/ml) for 48 h in Teflon jars, with or without gamma interferon (100 U/ml). Cells were then stained with the anti-FcRI antibodies (Ab 32.2 and 44.1) in an indirect immunofluorescence assay. Gamma interferon did not induce FcRI in the nonresponder monocytes (Fig. 5). Responder monocytes incubated in gamma interferon were stained more intensively with the anti-FcRI antibodies than monocytes incubated in medium alone. Similar results were obtained when monocytes were cultured for 7 d (in which case gamma interferon was added on day 0 and on day 5) (not shown). Neutrophils have
been shown to express FcRI after incubation for 18 h with gamma-interferon (7, 32). After incubation overnight with 100 U/ml of gamma interferon, neutrophils from responders stained positively with both Ab 32.2 and 44.1, while neutrophils from the four nonresponders were completely negative (Fig. 6). These results demonstrate that the FcRI defect was not restricted to the mononuclear phagocyte lineage.

**Phagocytosis of IgG-coated SRBC.** To study FcR-mediated phagocytosis, we incubated unopsonized or IgG-sensitized SRBC with monocytes from responder subjects and from nonresponders. As can be seen in Fig. 7, the number of particles phagocytosed per monocyte per hour was not different between responders and nonresponders. Even at low SRBC/monocyte ratios, or when the SRBC were opsonized with suboptimal doses of the antiserum, no difference between the two groups was detected (not shown). Ab IV.3 (anti-FcRII) almost completely blocked phagocytosis by nonresponder monocytes but not by responder monocytes (Fig. 8). This indicates that in nonresponder monocytes, phagocytosis was completely mediated by FcRII, while in responders, both FcRI and FcRII were responsible for ingestion of the IgG-coated particles.

**Effect of the FcRI defect on other immune functions.** All four nonresponder subjects had normal serum levels of IgA, IgG, and IgM. None of them had circulating rheumatoid factors (latex agglutination test), or anti-nuclear antibodies. Anti-thyroid cytoplasm antibodies were detected in low titer (1/80) in the serum of one of the subjects, without evidence of thyroid dysfunction (normal T3 and T4 thyroid hormone and thyroid stimulating hormone levels). No anti-parietal cell antibodies, antimitochondrial antibodies, antisMOOTH-muscle antibodies or antistriped muscle antibodies were detected in any of the subjects. No circulating immune-complexes were detected. Peripheral blood lymphocytes normally proliferated in vitro in response to four different common exogeneous antigens (stimulation index > 10 to at least three of the four anti-

**Figure 5.** Gamma interferon does not induce FcRI expression in nonresponder monocytes. E-rosette-negative cells (10⁶/ml) from control (responder) subjects and from OKT3-nonresponders were cultured in complete medium with 12% NHS for 48 h in Teflon jars, in the presence or absence of recombinant gamma interferon (100 U/ml). Cells were then washed and stained with Ab 32.2 and FITC-conjugated (F(ab')2) goat anti-mouse IgG (as explained in the legend to Fig. 4). Control monocytes incubated in gamma interferon expressed more FcRI than monocytes incubated in medium. However, nonresponder monocytes did not stain with anti-FcRI whether incubated in medium or in gamma interferon.

**Figure 6.** Expression of FcRI on neutrophils after incubation with gamma interferon. Neutrophils (10⁶ cells/ml) were incubated overnight in medium alone, or with 100 U/ml of gamma interferon. The expression of FcRI was then examined by staining with anti-FcRI antibody 44.1. (a) neutrophils stained with the second label antibody alone (FITC-conjugated F(ab')2 fragments of goat anti-mouse IgG). (b) Neutrophils incubated in medium and stained with Ab 44.1 and the second label antibody. (c) Neutrophils incubated in gamma interferon and stained with Ab 44.1 and the second label antibody.

**Figure 7.** FcR-mediated phagocytosis of IgG-coated SRBC by monocytes from control (responder) subjects (open symbols) and OKT3-nonresponders (closed symbols). PBMC, adjusted to a concentration of 5 x 10⁶ monocytes per ml, were incubated at 37°C in complete medium with 10% FCS for 1 h with a 200-μl volume of 51Cr-labeled SRBC, either sensitized (rabbit anti-SRBC antibodies) or unsensitized, at different monocyte/erythrocyte ratios. After incubation, nonphagocytosed SRBC were lysed with ammonium chloride in TRIS buffer and the cells were washed twice. Monocyte associated 51Cr was counted in a gamma-scintillation counter and the number of sensitized SRBC phagocytosed per monocyte was calculated.

**Figure 8.** Effect of Ab IV.3 (anti-FcRII) on FcR-mediated phagocytosis of IgG-coated SRBC. The phagocytosis assay was carried out with monocytes from responder (control) subjects and from nonresponders as explained in the legend to Fig. 7 at a monocyte/SRBC ratio of 1/40. However, before addition of SRBC, the monocytes in a 120-μl vol were incubated at 4°C with medium alone or with 20 μl of Ab IV.3 (hybridoma supernatant) for 30 min. Ab IV.3 blocked phagocytosis by nonresponder monocytes, but only partially reduced phagocytosis by responder (control) monocytes.
The hypothesis bodies, it bind given nonresponder expression. The present paper of Discussion was in injection *1 mo* after third vaccination, three vaccine doses were given with a 1-mo interval. Booster injection was given 12 mo later.

1 Geometric mean of antibody titters in a control group of 25 medical students (aged 20–30).

2 The geometric mean of anti-HBs titer (determined with the Abbott assay) 1 mo after booster injection, was reported to be 12,313 IU/liter in a study by Courouce, A.M., A. Laplanche, E. Benhamou, P. Jungers, J. Crosnier, and F. Degos, presented at the "Hepatitis B vaccine symposium: new findings and perspectives" in Bern (Switzerland), 5 September 1984. In this study, Hecav B booster injection was given to 152 medical staff members of hemodialysis units.

gens used) indicating a normal antigen presenting capacity of the monocytes. There was a normal distribution of lymphocyte subpopulations (T4, T8, NK, and B) in peripheral blood. One of the nonresponders was vaccinated with hepatitis B surface antigen and had a normal primary and secondary antibody response (Table I).

**Discussion**

The present paper describes a new defect of FcRI on phagocytic cells in four healthy subjects. Our previous reports on the unresponsiveness of T cells to the monoclonal antibody OKT3 in cultures of PBMC from these subjects had already made it clear that their monocytes were unable to bind the Fc portion of mlgG2a (23, 24). The experiments presented here demonstrate that the underlying abnormality is a defect of monocyte FcRI expression. This was demonstrated with three different assays: binding of monomeric mlgG2a-FITC and HulgG-FITC as analyzed with a FACS, binding of radioactive ligand (125I-HulgG) and rosette formation with anti-D-coated HuRBC. The results are compatible with the conclusion that the receptor is either absent or is structurally altered and unable to bind HulgG and mlgG2a. The fact that two monoclonal antibodies, detecting different epitopes on FcRI, did not stain the nonresponder monocytes, supports (but does not yet prove) the hypothesis of absence (rather than structural alteration) of the receptor. It is not possible to be entirely sure that there is not a small finite number of receptors beyond the capacity of the assays to enumerate. We have shown that the FcRI defect was not restricted to the mononuclear phagocytic cell lineage, but that neutrophils (after preincubation with gamma interferon) were also unable to express the FcRI. Still, this does not exclude the possibility that the FcRI defect is a developmental one. It would therefore have been interesting to study tissue macrophages of these nonresponder subjects (e.g., obtained by bronchoalveolar lavage). Unfortunately, this was not possible. It is highly unlikely that the nonresponder monocytes have a variant FcRI with low affinity for IgG, because aggregated IgG also did not bind to the monocytes after blockade of FcRII with Ab IV.3. The finding that no cytophilic IgG was detected on freshly isolated nonresponder monocytes excludes the possibility that the FcRI was blocked by binding of immune complexes.

The findings could be explained by a major mutational change in the structure of the receptor resulting in inability to bind IgG, and lack of expression of the epitopes recognized by Ab32.2 and 44.1. Alternatively, we might consider the possibility that the gene for FcRI is deleted or not expressed. We found that gamma-interferon did not induce FcRI expression in nonresponder monocytes, which argues against a regulatory defect in FcRI expression. Studies using the appropriate DNA-probes might help us to delineate more accurately the molecular basis of the FcRI defect.

Inability to bind mlgG2a in the nonresponder subjects underlies the lack of monocyte helper function in the support of mlgG2a anti-CD3 induced T cell mitogenesis. Indeed, interaction of anti-CD3 with both the CD3 molecule on the T cell, and with an FcRI on the monocyte, is an essential requirement for T cell activation with anti-CD3 (25). Until now these subjects are the only OKT3-nonresponders described, while unresponsiveness to mlgG1 anti-CD3 antibodies (e.g., anti-Leu 4) is frequent (~30% of Caucasians). It has to be emphasized that the underlying defect of nonresponders to mlgG2a anti-CD3 is quite different from that of mlgG1 anti-CD3 nonresponders. Monocytes of the latter group of nonresponders are unable to bind the Fc part of mlgG1 to FcRII (34). This is not due to the absence of FcRII, but rather to a genetically determined dimorphism of the FcRII, as demonstrated by isoelectric focusing experiments on isolated FcRII molecules (35). The alleles of both variants are about equally distributed in the population. Since only one of the two variant forms is able to bind mlgG1 (while both can bind complexed HulgG), homoyzgotes for the type of FcRII that is unable to bind mlgG1 will be nonresponders to mlgG1 anti-CD3. This has no implications for their mononuclear phagocytic system in view of the apparent normal ability of this variant of FcRII to bind complexed HulgG. The defective expression of phagocyte FcRI in the subjects described in this paper is thus a different situation. One would expect the absence of functional FcRI to be associated with a severe immune defect (16–22). Surprisingly, these monocytes normally ingested (even suboptimally opsonized) IgG-coated SRBC, and this was exclusively mediated through FcRII, as demonstrated by the blocking experiments with Ab IV.3. Based on immunofluorescence intensity obtained with Ab IV.3, the density of FcRII did not appear to be increased on nonresponder monocytes. The monocytes (similar to control monocytes) also did not express detectable levels of FcRIII. Thus a compensatory increase in FcRII density or an unusual expression of FcRIII did not account for normal phagocytosis. The lack of functional incompetence of monocyte FcRI also has not resulted in any clinical pathology. No circulating immune complexes were detected, no autoimmune pathology was present, and the specific antibody response (primary and secondary) to a viral antigen were completely normal. These latter experiments were carried out in view of the data that FcRI might be involved in antigen presentation via membrane bound antibodies (19, 20). It thus appears that FcRI might not be essential for survival, and perhaps does not have an important role in body defenses. It is also possible that

**Table I. Anti-HB-s Ag Antibody Response after Vaccination**

<table>
<thead>
<tr>
<th>Time of sampling</th>
<th>Serum anti-HBs-antibody titer (IU/liter)</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Nonresponder</td>
</tr>
<tr>
<td>Pre vaccination</td>
<td>0</td>
</tr>
<tr>
<td>1 mo after third vaccination</td>
<td>700</td>
</tr>
<tr>
<td>Before booster injection</td>
<td>280</td>
</tr>
<tr>
<td>1 mo after booster</td>
<td>35,990</td>
</tr>
</tbody>
</table>

* Antibody titters were determined with the commercial Abbott assay and are expressed in international units per liter. For primo-vaccination, three vaccine doses were given with a 1-mo interval. Booster injection was given 12 mo later.

1 The geometric mean of antibody titters in a control group of 25 medical students (aged 20–30).

2 The geometric mean of anti-HBs titer (determined with the Abbott assay) 1 mo after booster injection, was reported to be 12,313 IU/liter in a study by Courouce, A.M., A. Laplanche, E. Benhamou, P. Jungers, J. Crosnier, and F. Degos, presented at the "Hepatitis B vaccine symposium: new findings and perspectives" in Bern (Switzerland), 5 September 1984. In this study, Hecav B booster injection was given to 152 medical staff members of hemodialysis units.

576 J. L. Ceuppens, M. L. Baroja, F. Van Vaeck, and C. L. Anderson
FcRI is important, but that most functions of FcRI were taken over in this particular situation of nonresponder subjects by the other FcRs. FcRII and FcRIII, although they have low affinity for monomeric IgG, can efficiently bind immune complex or particle-bound IgG (4, 33). Clarkson et al. injected an anti-FcRIII antibody in primates. They observed that this antibody prolonged in vivo clearance of model immune complexes from an initial clearance half-time of 90 min to 4,095 min immediately after infusion (36). These results stress the dominant importance of FcRIII for removal of immune complexes in vivo. FcRIII is expressed on two types of phagocytic cells: neutrophils and macrophages (but not monocytes) (11). Moreover, complement receptors on the monocytes and the macrophages may also be important in the removal of immune complexes (37). C3bi receptors, similar to FcRII and FcRIII receptors, are normally present on the phagocytic cell membranes of the four subjects described here. All this probably explains when they had normal immune function in spite of a major FcR defect, restricted however to only one type of FcR.

Apart from the description of a unique FcRI defect, our data also provide some additional information on monocyte FcR function. It has never been unequivocally demonstrated before that FcRII on monocytes can mediate phagocytosis of IgG-coated particles. This is due to inability of blocking specifically FcRI function, while leaving FcRII intact. The results obtained with nonresponder monocytes now clearly demonstrate that FcRII indeed can mediate phagocytosis independently. The data also unequivocally demonstrate that normal FcRI function is required for binding of monomeric HulG and mlG2a to monocytes, and that the cytophilic IgG on circulating monocytes from healthy subjects is fixed by FcRI. The findings should stimulate further work on the differential function and relative importance of the distinct types of FcRs on phagocytic cells.

Acknowledgments

We are grateful to the members of the OKT3-nonresponder family for their cooperation and blood donations. We also thank Prof. J. Desmyter (Laboratory of Virology, University Hospital and Rega Institute, University of Leuven, Belgium) for determination of hepatitis B-surface antibodies; Professor B. Van Camp and Dr. M. Dewaele (Division of Immunology, Free University of Brussels, Brussels) for the use of the FACS-Star in their laboratory; and Ria Timmermans for secretarial assistance in the preparation of this manuscript.

This work was supported by a grant from the Belgian National Fund for Scientific Research (1.5.386.87N).

References


